Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $177.00 to $207.00. They now have an "outperform" rating on the stock.
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Sanford C. Bernstein from $157.00 to $197.00. They now have a "market perform" rating on the stock.
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma [Seeking Alpha]
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy